Dr Lal Path Labs to acquire 70% stake in SN Genelab for up to INR 168 Cr
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Smallcap 250 and 0.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lal Path Labs will acquire a 70% stake in SN Genelab Private Limited, a Gujarat-based genomics diagnostics firm, for up to INR 168 Crores plus a performance-linked earn out capped at INR 31.5 Crores. Post-acquisition, SN Gene will become a subsidiary. SN Gene reported turnover of INR 57.96 Crores in FY26, INR 53.36 Crores in FY25, and INR 43.27 Crores in FY24. The deal is all-cash, not a related party transaction, and aims to strengthen the company's genomics expertise. Expected to close by November 30, 2026.
Expands Dr Lal Path Labs into genomics diagnostics, broadening its advanced test portfolio. Cash deal, likely mildly positive given strategic fit and growing revenue base of target.